Comparison 12.

All DAA versus placebo/no intervention

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Without significant reductions in ALT/AST serum levels	11	2099	Risk Ratio (M‐H, Random, 95% CI)	0.79 [0.68, 0.92]
2 Without significant reductions in ALT/AST serum levels ‐ according to DAA status	11	2099	Risk Ratio (M‐H, Random, 95% CI)	0.79 [0.68, 0.92]
2.1 Trials assessing DAAs on or on the way to the market	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 Trials assessing DAAs withdrawn from market	11	2099	Risk Ratio (M‐H, Random, 95% CI)	0.79 [0.68, 0.92]
3 Without significant reductions in ALT/AST serum levels ‐ according to type of drug	11	2099	Risk Ratio (M‐H, Random, 95% CI)	0.79 [0.68, 0.92]
3.1 Faldaprevir	8	2019	Risk Ratio (M‐H, Random, 95% CI)	0.81 [0.69, 0.96]
3.2 Balaparavir	3	80	Risk Ratio (M‐H, Random, 95% CI)	0.61 [0.41, 0.92]